Effect of a novel inhibitory mAb against β-subunit of F1F0 ATPase on HCC

Cancer Biology and Therapy

Volumn 7, Issue 11, 2008, Pages 1830-1836

  Wang, Jingbo ^a   Han, Ying ^a   Liang, Jie ^a   Cheng, Xin ^a   Yan, Li ^a   Wang, Yingmei ^a   Liu, Jingmei ^a   Luo, Guanhong ^a   Chen, Xiong ^a   Zhao, Lina ^a   Zhou, Xinmin ^a   Wu, Kaichun ^a   Fan, Daiming ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

subunit of F1F0 ATPase; HCC; mAb; Plasma membrane molecule; Tumor therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 6F2C4; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BETA CHAIN; CANCER INHIBITION; CANCER MODEL; CATALYSIS; CELL MEMBRANE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; ENZYME INHIBITION; ENZYME SYNTHESIS; EXTRACELLULAR SPACE; FLOW CYTOMETRY; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 56449113875     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7:237-57.
2. Capaldi RA, Aggeler R. Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor. Trends Biochem Sci 2002; 27:154-60.
3. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999; 96:2811-6.
4. Moser TL, Kenan DJ, Ashley TA, Roy JA, Goodman MD, Misra UK, Cheek DJ, Pizzo SV. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98:6656-61.
5. + transporting ATP synthase on the surface of tumor cell lines. J Exp Med 1994; 180:273-81.
6. Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res 2006; 66:875-82.
7. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421:75-9.
8. Yonally SK, Capaldi RA. The F(1)F(0) ATP synthase and mitochondrial respiratory chain complexes are present on the plasma membrane of an osteosarcoma cell line: An immunocytochemical study. Mitochondrion 2006; 6:305-14.
9. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994; 59:471-82.
10. Wahl ML, Owen CS, Grant DS. Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. Endothelium 2002; 9:205-16.
11. Smirnoff P, Roiz L, Angelkovitch B, Schwartz B, Shoseyov O. A recombinant human RNASET2 glycoprotein with antitumorigenic and antiangiogenic characteristics: expression, purification and characterization. Cancer 2006; 107:2760-9.
12. Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, Smirnoff P, Hu GF, Lev D, Bar-Eli M. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis and metastasis. Cancer Res 2007; 67:5258-66.
13. Wahl ML, Grant DS. Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. Gen Pharmacol 2000; 35:277-85.
14. Li X, Fan R, Zou X, Gao L, Jin H, Du R, Xia L, Fan D. Inhibitory effect of recombinant adenovirus carrying immunocaspase-3 on hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 358:489-94.
15. Gao J, Chen C, Hong L, Wang J, Du Y, Song J, Shao X, Zhang J, Han H, Liu J, Fan D. Expression of Jagged1 and its association with hepatitis B virus X protein in hepatocellular carcinoma. Biochem Biophys Res Commun 2007; 356:341-7.
16. Li Q, Yan W, Cheng S, Guo S, Wang W, Zhang Z, Wang L, Zhang J, Wang W. Introduction of G1 phase arrest in Human Hepatocellular carcinoma cells (HHCC) by APMCF1 gene transfection through the downregulation of TIMP3 and upregulation of the CDK inhibitors p21. Mol Biol Rep 2006; 33:257-63.
17. Liang S, Lin T, Ding J, Pan Y, Dang D, Guo C, Zhi M, Zhao P, Sun L, Hong L, Shi Y, Yao L, Liu J, Wu K, Fan D. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med 2006; 84:764-73.
18. Ishikawa T, Muller M, Klunemann C, Schaub T, Keppler D. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATPdependent transport system for glutathione S-conjugates. J Biol Chem 1990; 265:19279-86.
19. Wang W, Sun J, Nimtz M, Deckwer WD, Zeng AP. Protein identification from twodimensional gel electrophoresis analysis of Klebsiella pneumoniae by combined use of mass spectrometry data and raw genome sequences. Proteome Sci 2003; 1:6.
20. Burwick NR, Wahl ML, Fang J, Zhong Z, Moser TL, Li B, Capaldi RA, Kenan DJ, Pizzo SV. An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chem 2005; 280:1740-5.
21. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832-8.
22. Liu N, Bi F, Pan Y, Sun L, Xue Y, Shi Y, Yao X, Zheng Y, Fan D. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity. Clin Cancer Res 2004; 10:6239-47.
23. He QY, Chen J, Kung HF, Yuen AP, Chiu JF. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004; 4:271-8.
24. Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG. Downregulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005; 65:3162-70.
25. Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, Kenan DJ, Lipes BD, Johnson CE, Marusich MF, Capaldi RA, Dewhirst MW, Pizzo SV. Angiostatinlike activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res 2007; 67:4716-24.
26. Yamamoto K, Shimizu N, Obi S, Kumagaya S, Taketani Y, Kamiya A, Ando J. Involvement of cell-surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am J Physiol Heart Circ Physiol 2007.
27. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-65.
28. Prescott DM, Charles HC, Poulson JM, Page RL, Thrall DE, Vujaskovic Z, Dewhirst MW. The relationship between intracellular and extracellular pH in spontaneous canine tumors. Clin Cancer Res 2000; 6:2501-5.
29. Yamagata M, Tannock IF. The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer 1996; 73:1328-34.
30. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989; 49:4373-84.
31. + exchange by serum. J Biol Chem 1991; 266:1551-6.
32. Berger K, Sivars U, Winzell MS, Johansson P, Hellman U, Rippe C, Erlanson-Albertsson C. Mitochondrial ATP synthase-a possible target protein in the regulation of energy metabolism in vitro and in vivo. Nutr Neurosci 2002; 5:201-10.
33. +-ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 2003; 1:931-9.
34. Zheng J, Ramirez VD. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun 1999; 261:499-503.
35. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Br J Pharmacol 2000; 130:1115-23.
36. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2:689-92.
37. Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin's molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 2005; 96:242-61.
38. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15:5268-82.
39. Ackerman ME, Chalouni C, Schmidt MM, Raman VV, Ritter G, Old LJ, Mellman I, Wittrup KD. A33 antigen displays persistent surface expression. Cancer Immunol Immunother 2008.
40. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003; 63:1288-96.
41. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency and stability. Cancer Immunol Immunother 2008.